Gordon G is a researcher with a focus on neuroscience, neurobiology, and neurovascular coupling. His work explores astrocyte function, cilia signaling, and stress impacts on synaptic plasticity, as evidenced by publications in journals like Nature Neuroscience and Nature Communications . Collaborations span institutions in Canada, the U.S., and Germany. Research Interests Neuroscience Neurovascular Coupling Astrocyte Signaling Metabolic Regulation Stress-Induced Neurological Impairment Computational Antibody Design Recent Article Trends His 2024-2025 studies highlight primary cilia in astrocytes, lactate biosensors for brain imaging, and computational antibody humanization. Earlier works (2020-2023) address stress-related synaptic plasticity and cerebrovascular dysfunction linked to CD2AP deficiency.
Roger Cone is a Research Professor at the University of Michigan, holding roles as the Mary Sue Coleman Director of the Life Sciences Institute and Vice Provost of the Biosciences Initiative. He is also a Tadataka Yamada Distinguished University Professor of Molecular and Integrative Physiology in the Medical School and a Professor in the Department of Molecular, Cellular, and Developmental Biology at LSA. His research focuses on the central nervous system’s regulation of energy storage, with emphasis on obesity, cachexia, and anorexia nervosa. Key contributions include studies on the melanocortin system’s role in energy homeostasis and its implications for metabolic disorders. His academic positions include leadership in interdisciplinary initiatives, bridging life sciences and medical research. Research highlights include identifying MC3R and MC4R receptor functions, linking nutritional state to growth and puberty timing, and exploring therapeutic targets for obesity. Cone collaborates with labs and teams globally, contributing to drug development (e.g., Setmelanotide) and genetic studies of eating disorders. His work integrates neuroscience, endocrinology, and pharmacology, addressing both fundamental mechanisms and clinical applications. Key affiliations include the University of Michigan Life Sciences Institute and Medical School, with administrative oversight of biosciences initiatives. His research is supported by grants focusing on melanocortin pathways, leptin sensitivity, and metabolic disease mechanisms. Collaborations involve multidisciplinary teams, emphasizing translational research from basic science to clinical trials.
Mila Welling is a researcher in the Department of Pediatrics at Erasmus MC, Rotterdam, focusing on genetic and metabolic causes of obesity. Her work bridges clinical pediatrics and molecular endocrinology, with a strong emphasis on personalized treatment strategies for patients with defects in the leptin-melanocortin pathway. Her research interests include: Genetic obesity syndromes, particularly MC4R deficiency Pharmacological interventions such as setmelanotide, liraglutide, and naltrexone-bupropion Diagnostic approaches for monogenic obesity Longitudinal growth and neurodevelopmental patterns in obese pediatric populations Real-world effectiveness of antiobesity drugs Cellular signaling mechanisms in melanocortin receptors The analysis of her recent publications reveals a consistent focus on translating genetic insights into clinical practice. Her studies span from basic science investigations of receptor function to large-scale clinical reviews and real-world observational data, demonstrating a multidisciplinary approach that integrates molecular biology, pharmacology, and patient-centered outcomes. A significant trend is the evaluation of novel and repurposed pharmacotherapies for rare obesity disorders, aiming to improve both metabolic parameters and quality of life. She has contributed to high-impact journals such as Endocrine Reviews , Obesity , and EClinicalMedicine , often collaborating with leading experts in endocrinology and pediatric metabolism. Notably, her 2025 review in Endocrine Reviews provides a comprehensive framework for antiobesity pharmacotherapy in genetically defined patients, positioning her as an emerging authority in this niche. There are no listed scientific awards in the provided data. Mila Welling completed her doctoral thesis titled Diagnostics and personalized treatment of genetic obesity in January 2025, indicating she is a recent PhD graduate. While no formal students are listed under her supervision, her role as a primary contributor to multiple peer-reviewed studies suggests active involvement in research mentorship and collaborative science. There is no mention of independent grant funding, though her participation in multi-author studies implies involvement in larger funded projects. She is actively engaged in research within the pediatric endocrinology group at Erasmus MC, working closely with senior researchers including Prof. Eric F.C. van Rossum and Dr. Elise L.T. van den Akker. Her work appears to be integrated into a broader network studying obesity genetics and treatment, likely part of a dedicated research team or laboratory focused on metabolic diseases in children.
Mariëtte Boon is an Assistant Professor in the Department of Internal Medicine at Erasmus MC . Her research focuses on the intersection of stress physiology, hormonal regulation, and obesity, with particular emphasis on glucocorticoid mechanisms, HPA axis dysregulation, and metabolic consequences of chronic stress. She has contributed to both clinical and translational studies involving patients with obesity and genetic endocrine disorders. Research Interests: Endocrine mechanisms underlying obesity Stress-hormone interactions (cortisol/cortisone) Longitudinal studies on growth and metabolic dysfunction Pharmacological interventions for obesity Her publications analyze biomarkers like hair cortisol, appetite-regulating hormones, and genetic factors (e.g., MC4R deficiency) to understand obesity pathophysiology. Articles emphasize translational applications, linking basic endocrine research to clinical obesity management strategies. Grants & Advising: While specific grants aren't listed, her collaborative work suggests involvement in multidisciplinary research teams. No formal advisee list is provided in the text. Labs/Teams: Not explicitly mentioned in the provided material .
Professor Sadaf Farooqi serves as Professor of Metabolism and Medicine and Wellcome Trust Principal Research Fellow at the University of Cambridge's Institute of Metabolic Science, leading pioneering research on the genetic and physiological basis of human energy balance disorders. Her research program centers on: Severe Childhood Obesity: Directing the Genetics of Obesity Study (GOOS) with over 7,000 global participants to identify mutations in leptin pathways and neural regulators of appetite Thinness Mechanisms: Investigating heritable thinness through the UK-based STILTS cohort of 4,000 individuals with BMI 2 Translational Applications: Developing clinical diagnostics, treating congenital leptin deficiency cases worldwide, and conducting trials of MC4R agonists like Setmelanotide Major recognitions include: Wellcome Trust Principal Research Fellowship NIHR Senior Investigator Award Funding from Wellcome Trust, NIHR Cambridge Biomedical Research Centre, Bernard Wolfe Endowment, and Leducq Foundation supports her multidisciplinary team of clinical researchers, bioinformaticians, and nurses. She maintains active partnerships with biotechnology firms for target validation and clinical trials while operating through the Translational Research Facility and MRC Metabolic Diseases Unit. Her work has established the NHS Obesity Gene Panel for clinical diagnostics and generated novel therapeutic approaches for genetic obesity syndromes. The research group comprises specialized personnel including Senior Research Co-ordinator Dr. Rebecca Bounds, Clinical Research Associates, Principal Research Nurse Mrs. Elana Henning, and Data Manager Mrs. Angela Reynolds, all focused on bridging molecular discoveries to patient care through the GOOS and STILTS initiatives.
Miguel Angel Garcia Perez is a Professor in the Department of Genetics at the Faculty of Biological Sciences, Universitat de València, Spain. His academic and research career is deeply rooted in genetics, with a specialized focus on women's health, particularly during and after menopause. He leads research within the CARMEN Healthy ageing in women group, emphasizing genetic, metabolic, and hormonal factors influencing osteoporosis, frailty, and reproductive outcomes. Research Interests: His work spans several interconnected domains, including the genetics of bone metabolism, the impact of estrogen and phytoestrogens on vascular and skeletal health, genetic polymorphisms related to osteoporosis and cardiovascular risk, and the application of nutritional and lifestyle interventions (such as the Mediterranean diet and physical activity) in postmenopausal women. He also investigates assisted reproductive technologies and ethical issues in fertility. Publication Trends: A review of his recent publications reveals a consistent focus on postmenopausal health, with recurring themes in genetic associations (especially involving estrogen receptors, vitamin D, and Wnt pathways), biomarker discovery (including microRNAs), and clinical implications of hormonal changes. His research integrates molecular biology, epidemiology, and clinical data to understand disease mechanisms and improve preventive strategies. Scientific Awards: No specific awards are mentioned in the provided text. Advising and Grants: While no explicit list of students or grants is provided, his role as a thesis supervisor and active publication record suggest involvement in mentoring graduate students and securing research funding. His affiliation with a named research group (CARMEN) implies participation in collaborative projects and grant-supported work. Labs and Teams: He is a member of the research group CARMEN Healthy ageing in women , which focuses on interdisciplinary studies of aging in women, integrating genetics, endocrinology, and public health approaches.
Baran Ersoy is an Assistant Professor of Metabolism in Medicine at Weill Cornell Medical College's Department of Medicine, with his Assistant Professor appointment ongoing since 2016 and an upcoming promotion to Associate Professor starting in 2025. His research program investigates metabolic disorders through molecular mechanisms, focusing on the interplay between lipid metabolism, organ dysfunction, and metabolic diseases. Education Ph.D., University of California, San Francisco (2009) B.S., University of Kansas (2001) Research Focus Dr. Ersoy's research explores fundamental metabolic processes with emphasis on: Molecular pathways in non-alcoholic fatty liver disease (NAFLD) progression Thioesterase-mediated regulation of lipid metabolism and ER stress Genetic mechanisms underlying obesity and insulin resistance Adipose tissue thermogenesis and fatty acid activation Hepatic gluconeogenesis regulation through microbiome interactions Ceramide biosynthesis in cardiometabolic diseases Research Publications His publication portfolio demonstrates consistent focus on metabolic dysregulation across multiple organ systems, with recent work (2020-2025) emphasizing: thioesterase functions in liver metabolism, genetic obesity pathways, NAFLD mechanisms, and novel intersections between lung injury and metabolic disorders. Methodologies span molecular biology, transgenic models, and clinical-translational approaches. Grants and Funding Principal Investigator : Them1 Inhibitors for NAFLD Management (NCI, 2023-2028) Key Personnel : Gut Microbiome Regulation of Hepatic Gluconeogenesis (NIDDK, 2022-2027) Principal Investigator : Thioesterase-mediated Lipotoxicity in Liver/Adipose Tissue (NIDDK, 2021-2026)
